EP1589980A4 - Verfahren zur diagnose und behandlung voninterstitieller lungenerkrankung - Google Patents

Verfahren zur diagnose und behandlung voninterstitieller lungenerkrankung

Info

Publication number
EP1589980A4
EP1589980A4 EP03811670A EP03811670A EP1589980A4 EP 1589980 A4 EP1589980 A4 EP 1589980A4 EP 03811670 A EP03811670 A EP 03811670A EP 03811670 A EP03811670 A EP 03811670A EP 1589980 A4 EP1589980 A4 EP 1589980A4
Authority
EP
European Patent Office
Prior art keywords
diagnostic
treatment methods
pulmonary diseases
interstitial pulmonary
interstitial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03811670A
Other languages
English (en)
French (fr)
Other versions
EP1589980A2 (de
Inventor
Jeffrey A Whitsett
Stephan W Glasser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Publication of EP1589980A2 publication Critical patent/EP1589980A2/de
Publication of EP1589980A4 publication Critical patent/EP1589980A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP03811670A 2002-12-09 2003-12-09 Verfahren zur diagnose und behandlung voninterstitieller lungenerkrankung Withdrawn EP1589980A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43194902P 2002-12-09 2002-12-09
US431949P 2002-12-09
PCT/US2003/038915 WO2004056310A2 (en) 2002-12-09 2003-12-09 Methods of diagnosis and treatment of interstitial lung disease

Publications (2)

Publication Number Publication Date
EP1589980A2 EP1589980A2 (de) 2005-11-02
EP1589980A4 true EP1589980A4 (de) 2007-04-04

Family

ID=32681947

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03811670A Withdrawn EP1589980A4 (de) 2002-12-09 2003-12-09 Verfahren zur diagnose und behandlung voninterstitieller lungenerkrankung

Country Status (7)

Country Link
EP (1) EP1589980A4 (de)
JP (1) JP2006519588A (de)
CN (1) CN100401896C (de)
AU (1) AU2003302740A1 (de)
BR (1) BR0317132A (de)
CA (1) CA2507613A1 (de)
WO (1) WO2004056310A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009183176A (ja) * 2008-02-05 2009-08-20 Univ Of Tokyo Ｉｌ−１タイプｉｉレセプター遺伝子の欠損変異体マウス
EP2391379B1 (de) 2009-01-30 2017-08-02 Alphabeta AB Verbindungen und verfahren zur behandlung von morbus alzheimer
AU2010356144B2 (en) 2010-06-24 2015-06-04 Alphabeta Ab Compound and method for treatment of Alzheimer's disease and familial dementia
WO2012138284A1 (en) 2011-04-05 2012-10-11 Alphabeta Ab Amyloidosis target useful in methods of treatment and for screening of compounds
US20170296595A1 (en) * 2014-09-18 2017-10-19 North Carolina State University Mammalian Lung Spheroids and Lung Spheroid Cells and Uses Thereof
CN111972354B (zh) * 2019-05-24 2021-11-30 凯斯艾生物科技（苏州）有限公司 一种具有自身免疫特征的间质性肺炎模型的构建方法
EP3811777B1 (de) 2019-10-27 2024-07-31 Shanghai RAAS Blood Products Co., Ltd. Genetisch modifizierte nicht-menschliche tiere
CN111296364B (zh) * 2019-10-27 2022-06-24 上海莱士血液制品股份有限公司 一种基因改造的小鼠动物模型基因改造方法及其应用
EP4132470A4 (de) * 2020-04-08 2023-11-08 Arizona Board of Regents on behalf of the University of Arizona Zusammensetzungen und verfahren zur behandlung und prävention von lungenerkrankungen
CN115772539B (zh) * 2022-11-17 2024-06-21 南京医科大学 一种具有ⅰ型气管发育不全表型的双侧肺脏缺失小鼠模型及其构建方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047623A1 (en) * 1999-02-12 2000-08-17 Chiesi Farmaceutici S.P.A. Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant
WO2000076535A1 (en) * 1999-06-11 2000-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)
WO2001080633A2 (en) * 2000-04-26 2001-11-01 Children's Hospital Medical Center Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
US6458759B1 (en) * 1996-04-26 2002-10-01 Ony, Inc. Compositions and methods for isolating lung surfactant hydrophobic proteins SP-B and SP-C
US20030221199A1 (en) * 1998-10-20 2003-11-27 Whitsett Jeffrey A. Surfactant protein D for the prevention and diagnosis of pulmonary emphysema

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE165606T1 (de) * 1993-01-13 1998-05-15 Ajinomoto Kk Zelloberflächenprotein aus brevibakterium lactofermentum

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458759B1 (en) * 1996-04-26 2002-10-01 Ony, Inc. Compositions and methods for isolating lung surfactant hydrophobic proteins SP-B and SP-C
US20030221199A1 (en) * 1998-10-20 2003-11-27 Whitsett Jeffrey A. Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
WO2000047623A1 (en) * 1999-02-12 2000-08-17 Chiesi Farmaceutici S.P.A. Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant
WO2000076535A1 (en) * 1999-06-11 2000-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)
WO2001080633A2 (en) * 2000-04-26 2001-11-01 Children's Hospital Medical Center Surfactant protein d for the prevention and diagnosis of pulmonary emphysema

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AMIN R S ET AL: "Surfactant protein deficiency in familial interstitial lung disease.", THE JOURNAL OF PEDIATRICS. JUL 2001, vol. 139, no. 1, July 2001 (2001-07-01), pages 85 - 92, XP002394844, ISSN: 0022-3476 *
DAVIS A J ET AL: "Lung function in premature lambs and rabbits treated with a recombinant SP-C surfactant.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE FEB 1998, vol. 157, no. 2, February 1998 (1998-02-01), pages 553 - 559, XP002418346, ISSN: 1073-449X *
GLASSER S W ET AL: "Altered stability of pulmonary surfactant in SP-C-deficient mice.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 22 MAY 2001, vol. 98, no. 11, 22 May 2001 (2001-05-22), pages 6366 - 6371, XP002394842, ISSN: 0027-8424 *
GLASSER STEPHAN W ET AL: "Pneumonitis and emphysema in sp-C gene targeted mice.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 18 APR 2003, vol. 278, no. 16, 18 April 2003 (2003-04-18), pages 14291 - 14298, XP002394847, ISSN: 0021-9258 *
HAFNER D ET AL: "CYCLOOXYGENASE-INHIBITION ENHANCES THE EFFECTS OF RSP-C SURFACTANT THERAPY IN A RAT LAVAGE MODEL OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)", EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, JENA, DE, vol. 55, no. 1, July 2003 (2003-07-01), pages 59 - 68, XP009024125, ISSN: 0940-2993 *
IKEGAMI MACHIKO ET AL: "Deficiency of SP-B reveals protective role of SP-C during oxygen lung injury.", JOURNAL OF APPLIED PHYSIOLOGY (BETHESDA, MD. : 1985) FEB 2002, vol. 92, no. 2, February 2002 (2002-02-01), pages 519 - 526, XP002394843, ISSN: 8750-7587 *
NOGEE LAWRENCE M ET AL: "Mutations in the surfactant protein C gene associated with interstitial lung disease.", CHEST. MAR 2002, vol. 121, no. 3 Suppl, March 2002 (2002-03-01), pages 20S - 21S, XP009070987, ISSN: 0012-3692 *
SANFORD L P ET AL: "Influence of genetic background on knockout mouse phenotypes.", METHODS IN MOLECULAR BIOLOGY (CLIFTON, N.J.) 2001, vol. 158, 2001, pages 217 - 225, XP009071124, ISSN: 1064-3745 *
THOMAS ALAN Q ET AL: "Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 1 MAY 2002, vol. 165, no. 9, 1 May 2002 (2002-05-01), pages 1322 - 1328, XP002394845, ISSN: 1073-449X *

Also Published As

Publication number Publication date
WO2004056310A2 (en) 2004-07-08
CA2507613A1 (en) 2004-07-08
AU2003302740A1 (en) 2004-07-14
BR0317132A (pt) 2005-10-25
WO2004056310A3 (en) 2005-09-01
JP2006519588A (ja) 2006-08-31
CN100401896C (zh) 2008-07-16
CN1731932A (zh) 2006-02-08
EP1589980A2 (de) 2005-11-02

Similar Documents

Publication Publication Date Title
EP1565187A4 (de) Verfahren zur behandlung von krebs undverwandte verfahren
EP1390077A4 (de) Behandlung und diagnose vom makrophagen-vermittelter erkrankung
EP1495321A4 (de) Menschliche stoffwechselmodelle und -verfahren
EP1411849A4 (de) Gerät und verfahren zur behandlung von gewebe
EP1503685A4 (de) Implantierbares thermisches behandlungsverfahren und gerät
EP1465854A4 (de) Chalconderivate und deren verwendung zur behandlung von krankheiten
EP1540012A4 (de) Polymorphismen zur vorhersage einer krankheit und des behandlungsergebnisses
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
ATE413385T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
EP1555018A4 (de) Mittel zur behandlung von neurodegenerativen erkrankungen
EP1796625A4 (de) Neue fenofibrat-formulierungen und relevante behandlungsmethoden
NO20043359L (no) Anordning for ikke-invasiv ultralydbehandling av et objekt
DE60330693D1 (de) WuRMEBEHANDLUNGSVERFAHREN UND WuRMEBEHANDLUNGSVORRICHTUNG
EP1773405A4 (de) Verfahren zur diagnose, überwachung und behandlung von lungenerkrankungen
NO20043370L (no) N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
EP1539251A4 (de) Zusammensetzungen und verfahren zur diagnose und therapie von medizinischen erkrankungen mit angiogenese
ID27576A (id) Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun
IS7444A (is) Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum
EP1560572A4 (de) Topische parasitizidformulierungen und behandlungsverfahren
EP1589980A4 (de) Verfahren zur diagnose und behandlung voninterstitieller lungenerkrankung
EP1611120A4 (de) Neue verfahren zur behandlung von entzündlichen erkrankungen
EP1429775A4 (de) Verfahren zur behandlung von lungenerkrankungen
EP1692305A4 (de) Diagnose und behandlung von krankheiten durch defekte im tuberösen sklerosepfad
EP1682171A4 (de) Zusammensetzungen und verfahren zur behandlung von neurologischen erkrankungen
ATE369136T1 (de) Therapeutische behandlung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050609

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 61/00 20060101AFI20060404BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/00 20060101ALI20060828BHEP

Ipc: A01K 67/00 20060101ALI20060828BHEP

Ipc: G01N 33/00 20060101ALI20060828BHEP

Ipc: A61K 33/00 20060101ALI20060828BHEP

Ipc: A61K 31/00 20060101ALI20060828BHEP

Ipc: A01N 61/00 20060101AFI20060404BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070307

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/17 20060101ALI20070226BHEP

Ipc: C12N 15/00 20060101ALI20070226BHEP

Ipc: A01K 67/00 20060101ALI20070226BHEP

Ipc: G01N 33/00 20060101ALI20070226BHEP

Ipc: A61K 33/00 20060101ALI20070226BHEP

Ipc: A61K 31/00 20060101ALI20070226BHEP

Ipc: A01N 61/00 20060101AFI20060404BHEP

17Q First examination report despatched

Effective date: 20070615

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080701